Author affiliations: Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas (Michael E. Scheurer); Department of Pediatrics, Section of Hematology and Oncology, Baylor College of Medicine, Houston, Texas (Michael E. Scheurer); Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas (Carol J. Etzel, Mei Liu, Melissa L. Bondy); Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio (Jill Barnholtz-Sloan); Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden (Fredrik Wiklund); Department of Radiation Sciences, Oncology, Umeå University Hospital, Umeå, Sweden (Björn Tavelin, Beatrice S. Melin); and Department of Neurological Surgery, University of California, San Francisco, San Francisco, California (Margaret R. Wrensch).
Drs. Michael E. Scheurer and Carol J. Etzel contributed equally to this work. Drs. Beatrice S. Melin, Melissa L. Bondy, and Margaret R. Wrensch shared equally in the conception and execution of this work as senior authors from each site.
This work was supported by grants from the National Institutes of Health, Bethesda, Maryland (R01CA 070917, R01CA 052689, P50CA 097257, R01CA 123208, K07CA 093592, and K07CA 131505). Work at UCSF was also supported by grants from the National Brain Tumor Foundation; by the UCSF Lewis Chair in Brain Tumor Research; and by donations from families and friends of J. Berardi, H. Glaser, and E. Olsen. The Swedish study was supported by The Northern Sweden Cancer Foundation, Umeå University Cutting Edge research grants, the Swedish Cancer Foundation, and the Swedish Research Council. Beatrice S. Melin was supported by the Acta Oncologica Foundation through the Royal Swedish Academy of Science. Collection of California cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology, and End Results Program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California, and contract N01-PC-54404 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement 1U58DP00807-01 awarded to the Public Health Institute.
The authors acknowledge the contributions of the following individuals to the overall brain tumor research programs—MD Anderson Cancer Center: Georgina Armstrong (research manager) and Phyllis Adatto (project director); and University of California, San Francisco: Dr. John Wiencke (co-investigator) and Lucie McCoy (study coordinator). The authors also thank Kenneth Aldape and Tarik Tihan for pathology review. The UCSF researchers thank the following pathology departments for providing tumor specimens for review: Alexian, Alta Bates, Brookside, California Pacific, Doctors Pinole, Eden, El Camino, Good Samaritan, Highland, John Muir, Kaiser Redwood City, Kaiser San Francisco, Kaiser Santa Teresa, Los Gatos, Los Medanos, Marin General, Merrithew, Mills Peninsula, Mt. Diablo Hospital, Mt. Zion, Naval Hospital, O'Connor, Ralph K. Davies, Saint Louise, San Francisco General, San Jose, San Leandro, San Mateo County, San Ramon Valley, Santa Clara Valley, Sequoia, Seton, St. Francis, St. Luke's, St. Rose, Stanford, Summit, UC San Francisco, Valley Livermore, Veterans Palo Alto, Veterans SF, and Washington Hospitals and Medical Centers.
For more information about the GLIOGENE Consortium, refer to the following Web site: http://www.gliogene.org.
The members of the GLIOGENE Consortium: Department of Epidemiology, MD Anderson Cancer Center, The University of Texas, Houston, Texas (Georgina N. Armstrong, Melissa L. Bondy, Sanjay Shete); Department of Radiation Sciences Oncology, Umeå University, Umeå, Sweden (Ulrika Andersson, Beatrice S. Melin, Roger Henriksson); Baylor College of Medicine, Texas Children's Cancer Center, Houston, Texas (Ching Lau); Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom (Richard S. Houlston, Lindsay B. Robertson); Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut (Elizabeth B. Claus); Department of Neurosurgery, Brigham and Women's Hospital Boston, Boston, Massachusetts (Elizabeth B. Claus); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Jill Barnholtz-Sloan, Karen Devine, Gene Barnett, Andrew Sloan); The Neurological Institute of Columbia University, New York, New York (Rose Lai); Cancer Control and Prevention Program, Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina (Dora Il'yasova, Joellen Schildkraut); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York (Jonine L. Bernstein, Sara H. Olson, Lisa DeAngelis); Mayo Comprehensive Clinic Cancer, Mayo Clinic, Rochester, Minnesota (Robert B. Jenkins, Ping Yang, Amanda L. Rynearson); Department of Neurological Surgery, University of California, San Francisco, San Francisco, California (Margaret Wrensch, Lucie McCoy, John K. Wienkce); Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, Illinois (Bridget McCarthy, Faith Davis); Department of Neurology, NorthShore University HealthSystem, Evanston, Illinois (Nicholas A. Vick); Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark (Christoffer Johansen, Hanne Bødtcher); Cancer and Radiation Epidemiology Unit, Gertner Institute, Chaim Sheba Medical Center, Tel Hashomer, Israel (Siegal Sadetzki, Revital Bar-Sade Bruchim, Galit Hirsh Yechezkel); and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel (Siegal Sadetzki).
The ideas and opinions expressed herein are those of the author(s), and endorsement by the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their contractors and subcontractors is not intended nor should be inferred.
Conflict of interest: none declared.